- Home
- HR vs IONS Comparison
HR vs IONS Comparison
Compare HR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HR
- IONS
- Stock Information
- Founded
- HR 1992
- IONS 1989
- Country
- HR United States
- IONS United States
- Employees
- HR N/A
- IONS N/A
- Industry
- HR Real Estate Investment Trusts
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- HR Real Estate
- IONS Health Care
- Exchange
- HR Nasdaq
- IONS Nasdaq
- Market Cap
- HR 5.3B
- IONS 5.9B
- IPO Year
- HR 1993
- IONS 1991
- Fundamental
- Price
- HR $15.92
- IONS $43.00
- Analyst Decision
- HR Hold
- IONS Buy
- Analyst Count
- HR 5
- IONS 16
- Target Price
- HR $16.40
- IONS $58.25
- AVG Volume (30 Days)
- HR 4.2M
- IONS 2.0M
- Earning Date
- HR 08-01-2025
- IONS 07-31-2025
- Dividend Yield
- HR 7.79%
- IONS N/A
- EPS Growth
- HR N/A
- IONS N/A
- EPS
- HR N/A
- IONS N/A
- Revenue
- HR $1,240,776,000.00
- IONS $717,253,000.00
- Revenue This Year
- HR N/A
- IONS $7.98
- Revenue Next Year
- HR $2.47
- IONS $16.09
- P/E Ratio
- HR N/A
- IONS N/A
- Revenue Growth
- HR N/A
- IONS N/A
- 52 Week Low
- HR $14.09
- IONS $23.95
- 52 Week High
- HR $18.90
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- HR 68.33
- IONS 78.37
- Support Level
- HR $15.66
- IONS $39.37
- Resistance Level
- HR $16.09
- IONS $43.71
- Average True Range (ATR)
- HR 0.34
- IONS 1.36
- MACD
- HR 0.11
- IONS 0.44
- Stochastic Oscillator
- HR 84.83
- IONS 92.05
About HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.